By: Thomas W. Samuelson, MD; Jason Bacharach, MD; Murray Fingeret, OD, FAAO; Albert S. Khouri, MD; and Constance Okeke, MD, MSCE
This course has expired. You can still review the content but course credit is no longer available.
CONTENT SOURCE This continuing medical education (CME)/continuing education (CE) activity captures content from a roundtable discussion. ACTIVITY DESCRIPTION The development and commercialization of two new topical glaucoma drugs has renewed interest in medical therapy. In late 2017, after a 2-decade gap in glaucoma pharmacology innovation, two drugs in novel classes were approved for IOP reduction in eyes with ocular hypertension or open-angle glaucoma. These drugs lower IOP through unique mechanisms of action not previously available with existing drug choices. This activity will provide education on the efficacy, safety, and mechanism of action of these two new drugs.
Supported by unrestricted educational grants from Aerie and Bausch + Lomb.
Upon completion of this activity, the participant should be able to:
• Identify the mechanisms of action as well as the efficacy and safety profiles of novel trabecular outflow medications
• Demonstrate proficiency in selecting appropriate therapies to achieve individualized patient-specific treatment goals
• Advocate for patients who would benefit from new drugs before they are incorporated into payors’ formularies
ACCREDITATION STATEMENT
Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Evolve Medical Education designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Evolve is an approved COPE Administrator.
This course is COPE approved for 1.0 hour of CE Credit for optometrists.
COPE Course ID: 65953-GL
COPE Event ID: 118669
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity. The following faculty/staff members have the following financial relationships with commercial interests:
Jason Bacharach, MD, and/or spouse, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie, Allergan, Bausch + Lomb, Ellex, EyePoint, Glaukos, New World Medical, Optovue, and Osmotica. Grant/Research Support: Aerie, Allergan, Bausch + Lomb, Biorasi, Equinox, Eyepoint, Glaukos, Nicox, Optovue, Santen, and Sun. Speaker’s Bureau: Alcon, Allergan, Glaukos, and New World Medical. Stock/Shareholder: Aerie, Injectsense, and Osmotica.
Murray Fingeret, OD, FAAO, and/or spouse, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie, Allergan, Bausch + Lomb, and Novartis. Speaker’s Bureau: Aerie, Allergan, and Bausch + Lomb.
Albert S. Khouri, MD, and/or spouse, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie, Allergan, and Glaukos. Grant/Research Support: Allergan. Speaker’s Bureau: Aerie, Allergan, and Bausch + Lomb.
Constance Okeke, MD, MSCE, and or spouse, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie, Alcon, Bausch + Lomb, Ellex, Glaukos, Reichert and Sight Sciences. Grant/Research Support: Glaukos. Speaker’s Bureau: Aerie, Alcon, Bausch + Lomb, Ellex, Glaukos, and NeoMedix.
Thomas Samuelson, MD, and/or spouse, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: AcuMems, Aerie Pharmaceuticals, Akorn, Alcon Surgical, AMO (Abbott Medical Optics), AqueSys/Allergan, Bausch + Lomb, BELKIN Laser Inc., Endo Optiks, Equinox, Glaukos, lvantis, Ocular Surgery News, Ocuphire, PolyActiva, Santen, Shire, Sight Science, TearClear, Transcend Medical, Veracity Innovations LLC, and Vindico/Slack. Stock/Shareholder: Belkin Laser, Equinox, Glaukos, lvantis, Ocuphire, Sight Sciences, and Tear Clear.
EDITORIAL SUPPORT DISCLOSURES
Erin K. Fletcher, MIT, director of compliance and education; Susan Gallagher-Pecha, director of client services and project management; Cassandra Richards, director of education development, Evolve; and Michelle Dalton, writer, have no financial relationships with commercial interests. Nisha Mukherjee, MD, peer reviewer, have no financial relationships with commercial interests.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Glaucoma Today, Modern Optometry, Aerie, or Bausch + Lomb.
